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Health-related websites are an important source of information for the public. Increasing
public awareness of overdiagnosis and ductal carcinoma in situ (DCIS) in breast cancer
screening may facilitate more informed decision-making. This study assessed the extent to
which such information was included on prominent health websites oriented towards the




Websites identified through Google searches in England (United Kingdom) and New South
Wales (Australia) for “breast cancer screening” and further websites included based on our
prior knowledge of relevant organisations.
Main Outcomes
Content analysis was used to determine whether information on overdiagnosis or DCIS
existed on each site, how the concepts were described, and what statistics were used to
quantify overdiagnosis.
Results
After exclusions, ten UK websites and eight Australian websites were considered relevant
and evaluated. They originated from charities, health service providers, government
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agencies, and an independent health organisation. Most contained some information on
overdiagnosis (and/or DCIS). Descriptive information was similar across websites. Among
UK websites, statistical information was often based on estimates from the Independent UK
Panel on Breast Cancer Screening; the most commonly provided statistic was the ratio of
breast cancer deaths prevented to overdiagnosed cases (1:3). A range of other statistics
was included, such as the yearly number of overdiagnosed cases and the proportion of
women screened who would be overdiagnosed. Information on DCIS and statistical infor-
mation was less common on the Australian websites.
Conclusions
Online information about overdiagnosis has become more widely available in 2015–16
compared with the limited accessibility indicated by older research. However, there may be
scope to offer more information on DCIS and overdiagnosis statistics on Australian web-
sites. Moreover, the variability in how estimates are presented across UK websites may be
confusing for the general public.
Introduction
Overdiagnosis can be defined as the detection of a disease that would not cause symptoms or
death if it had remained undetected. It is a widely debated issue in breast cancer screening
since it can lead to unnecessary treatment (i.e. ‘overtreatment’), including surgery, radiother-
apy, hormone therapy, and chemotherapy. These can be associated with both short- and long-
term adverse effects in addition to the negative psychological consequences of becoming a
breast cancer patient [1]. Much overtreatment in breast screening is suspected to arise from the
unnecessary and unbeneficial detection of ductal carcinoma in situ (DCIS). Although DCIS
can become invasive, symptomatic, and a threat to life, it can also remain confined to the milk
ducts in which it arose, remaining asymptomatic throughout a woman’s lifetime [2].
Previous research has found both limited public awareness of overdiagnosis and widespread
misconceptions about it. When a survey sample of 500 Australian adults were asked what they
thought the term meant, only 41% were able to provide a definition that was considered
approximately correct (e.g. “exaggerating something that’s there”) [3] and a similar United
Kingdom (UK) study of 390 adults found that less than 1% of the general public could provide
a more precise definition (e.g. “diagnosis of a disease that will not cause symptoms or death”
(Ghanouni et al., under review). Members of the public often have difficulty understanding the
concept, and find it counterintuitive when it is explained [4, 5]. This suggests that there is sub-
stantial scope to improve how information on overdiagnosis is communicated.
A 2012 US survey found that 54% of adults aged 50 to 64 years had used the internet to
search for health information in the past year [6], suggesting that health websites are likely to
be an important way in which health concepts and recommendations are disseminated. In the
UK, the Cancer Research UK website [7] alone regularly receives over 1 million visits per
month [8]. However, a previous study evaluating 27 websites on breast cancer screening con-
cluded that information on overdiagnosis (and overtreatment) was often omitted or inaccurate
[9]. To our knowledge, although this study was published in 2004 (websites themselves were
accessed in 2002), it is the most recent appraisal of online information relating to overdiagnosis
in breast screening. However, there have been notable developments since then. For example,
controversy around whether screening invitees were being adequately informed about
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overdiagnosis [10] resulted in the commissioning of the Independent UK Panel on Breast Can-
cer Screening review (IUKPBCS) [2, 11] to estimate the magnitude of overdiagnosis and breast
cancer mortality reduction attributable to screening. Although health websites might be
expected to have incorporated the review’s findings into their information materials, this has
not been formally evaluated. Moreover, the web in 2016 bears little resemblance to the web as
it existed in 2002. Availability of broadband and internet usage among the general public have
increased [12], creating a greater incentive for producers of health content to provide high-
quality web-based information [13]. In addition, the increased bandwidth available to home
users has allowed content producers to offer information in formats other than simple text and
images, such as streaming video.
We evaluated information on overdiagnosis and DCIS provided by health websites oriented
towards the general public in the UK and Australia (and England and New South Wales).
These two countries were selected to allow an international analysis of English-language web-
sites in areas where breast cancer screening is offered as part of organised screening pro-
grammes that is free at the point of use. We looked at whether any such information was
provided, its content, and how it compared across websites, with particular focus on quantita-
tive information describing the magnitude of overdiagnosis in breast screening.
Materials and Methods
Website identification
Google has approximately a 90% market share among search engines [14], making it an impor-
tant intermediary between individuals seeking information on breast cancer screening and the
information source itself. Consequently, websites were selected based on a pair of Google
searches for “breast cancer screening”, carried out on 13th August 2015 for UK-oriented web-
sites and 14th December 2015 for Australia-oriented websites. These were performed using an
‘incognito’ window in Chrome (for Windows; Google, Mountain View, CA, USA) in order to
prevent cookies and user account data from influencing search results. The two searches were
carried out in the respective countries of interest, in order to ensure that results were tailored to
users from those countries. The first five pages of results (using the default number of results
per page) were scanned manually in order to identify potentially relevant websites. This was
anticipated to identify the vast majority of websites that users might realistically access: “click-
through rates” for links are less than 5% for websites listed lower than the top ten results [15].
The Google search was supplemented with the authors’ prior knowledge of resources that
contained relevant information and were anticipated to be commonly used. Search results were
excluded based on the following criteria: i) duplicate information sources (e.g. two links to the
same website), suggested secondary search queries (e.g. “breast cancer screening age”), or sub-
sidiary links (e.g. search results linking to information pages on “diagnosis” and “treatment”
within a single main result); ii) research articles, technical reports, or sites aimed at healthcare
professionals; iii) media releases or media articles (e.g. news stories); iv) websites from organi-
sations with a remit outside the UK or Australia, as applicable (e.g. the National Institutes of
Health in the United States); v) websites with a remit specific to a country (or state/territory)
within the United Kingdom (or Australia) other than England (or New South Wales; NSW);
vi) locally- or regionally-oriented websites (e.g. those of city-specific or county-wide breast
screening services). Although the web is generally accessible across national borders, healthcare
and screening systems are organised at a national level within the UK and at a state level in
Australia. Hence, we limited our analysis to websites from organisations that were either
focused on breast screening in England or NSW, or that related to the UK or Australia as a
whole, in order to obtain suitably homogenous sets of resources that could be interpreted
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within similar policy contexts. Finally, we excluded websites that did not provide information
on breast cancer screening.
Analysis
Websites were categorised as originating from either charities, health service providers, govern-
ment agencies, or other groups. They were evaluated using content analysis [16] to determine
i) whether they included any information on overdiagnosis, overtreatment or DCIS in breast
screening, ii) how overdiagnosis or DCIS was described, and iii) how overdiagnosis was quanti-
fied. Three authors browsed through websites manually with the aim of identifying all primary
information pages that referred to any of these aspects. Browsing was supplemented by using
the search functions built into websites, where these were available. Where relevant informa-
tion was located, the text was extracted and saved in an Excel 2010 spreadsheet (for Windows;
Microsoft, Redmond, WA, USA) for subsequent interpretation and comparison. Descriptions
of overdiagnosis, DCIS, and relevant statistics were evaluated independently by pairs of authors
who read the extracted text to identify what they considered to be the key information points,
which were then listed and summarised for each website. These were then counted and (where
possible) combined, in order to generate the number of websites containing each information
point. Authors compared their categorisations in case of any discrepancies, which were
resolved through discussion. The content of information was also compared across websites to
highlight similarities and differences.
Since all data were publically available and the study did not involve human participants,
the host institution considered this study to be exempt from requiring ethical approval.
Results
Website selection
The initial Google searches yielded 167 and 105 links for the UK and Australia, respectively.
Duplicate results, suggested secondary searches, and secondary subsidiary links were excluded
(UK: n = 112; Australia: n = 57), leaving 55 and 48 unique search results.
UK websites: Nine websites consisting of research articles, technical reports, or resources
aimed at healthcare professionals were excluded, as were 14 media articles, six websites with a
remit outside the UK, five websites with a remit specific to a UK country other than England,
and 11 regionally-focused websites within England. The ten remaining websites were searched
for information relating to breast cancer screening and a further three were excluded for not
providing any such information. Three websites were added based on authors’ prior knowledge
for a total of ten websites to be included in the analysis.
Australian websites: Five research articles/professional resources and nine media articles
were excluded. Nine websites with a remit outside Australia, nine region-specific websites out-
side NSW, and three region-specific websites within NSW were also excluded. Of the remain-
ing websites, five were excluded for not including information about breast screening, leaving a
total of eight websites to be analysed.
Website characteristics
UK websites: Six websites were from health charities (Against Breast Cancer, Breast Cancer
Care, Breast Cancer Now, Cancer Research UK, healthtalk.org, Macmillan Cancer Support) [7,
17–21], two were from health service providers (National Health Services [NHS] Choices, and
Public Health England) [22, 23], and one was from an independent health website (Patient)
[24]. In England, invitees to the NHS Breast Screening Programme are routinely posted an
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invitation leaflet that aims to provide enough information to allow women to make an
‘informed choice’ about their participation. An electronic version of the leaflet is accessible to
the general public online (currently available via Public Health England but hosted on a sepa-
rate website at the time of the analysis). Consequently, we evaluated this as well [25].
Australian websites: Three websites were from cancer charities (Breast Cancer Network
Australia, Cancer Council Australia and Cancer Council NSW) [26–28], two were from breast
screening service providers (BreastScreen Australia and BreastScreen NSW) [29–30], and three
were from government agencies (Australian Institute of Health and Welfare, Cancer Australia,
and Cancer Institute NSW) [31–33]. There was some overlap between organisations: the Can-
cer Council NSW is a member of the Cancer Council Australia (the national body of the char-
ity). BreastScreen NSW is part of BreastScreen Australia (the national breast cancer screening
programme) and is managed by the Cancer Institute NSW. As with the English Breast Screen-
ing Programme, the standard information leaflet provided to invitees in NSW is freely available
online. It is hosted on the BreastScreen NSW website and so we considered it part of that
resource for the purposes of this study.
Overdiagnosis and DCIS information
Descriptions within websites. UK websites: All but one of the websites included at least
some information on overdiagnosis. These nine websites used similar general definitions, refer-
ring to it in terms of detection of cancer that would never have caused a problem, harm, symp-
toms, or become life threatening if left undetected. Three websites used both the terms
‘overdiagnosis’ and ‘overtreatment’ (or terms with this same word root e.g. ‘overdiagnose’),
and a further two websites used one of the terms. Six websites mentioned that it was not possi-
ble to determine which breast cancers would become invasive, grow quickly, or become life
threatening for a given person diagnosed with breast cancer through screening. Seven websites
also raised the issue that (most) people diagnosed with breast cancer would receive treatment
and that this may be unnecessary in some cases. Furthermore, two websites made a categorical
statement regarding the harms of overtreatment in terms of emotional, psychological and
physical side effects.
Nine out of the ten websites included some information on DCIS, describing it as a form of
cancer that had not invaded the surrounding breast tissue (or spread beyond the milk ducts).
Of these nine websites, eight stated that it could become an invasive breast cancer if left
untreated and six related the disease to the concept of overdiagnosis. Eight websites also noted
that DCIS and screening were closely related, and four made the explicit point that treatment
for DCIS was highly effective or that the prognosis was very good. On seven websites, a link to
overdiagnosis was made in the form of statements that it was impossible to determine which
cases of DCIS would become invasive for a given person.
Australian websites: Six of the eight Australian websites included at least some information
on overdiagnosis. Information provided was similar across websites: five described overdiagno-
sis in terms of detection of breast cancer that would never have caused symptoms, health prob-
lems, or become life threatening. Five websites used the term ‘overdiagnosis’ and one also used
the term ‘overtreatment’. Six websites stated that it was impossible (or difficult) to determine
whether a specific breast cancer would become invasive or harmful. Two websites stated that
most people diagnosed with breast cancer would receive treatment, and one stated that unnec-
essary treatment was associated with harms.
The kinds of information provided about DCIS were similar to the UK websites: four web-
sites gave a description of what it was (e.g. in terms of being a form of breast cancer that is cur-
rently confined to the milk ducts and has not become invasive). Two stipulated that DCIS
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could become invasive if left untreated (or even with treatment), and went on to state that it
was not possible to determine whether a particular DCIS case would become invasive and that
screening was a common pathway by which women might be diagnosed. Two websites were
explicit that DCIS was the type of breast cancer to which overdiagnosis was more likely to
apply, and one stated that most women treated for DCIS would not go on to develop invasive
breast cancer.
Statistics within websites. UK websites: Websites varied considerably in terms of the sta-
tistics used to describe the magnitude of overdiagnosis. There were a few recurring examples:
the statement that 4,000 women (in the UK) are overdiagnosed or overtreated (through screen-
ing) each year was present on three websites. Two websites stated that 3 in 200 women
screened (every three years between age 50 and 70 years) would be overdiagnosed or over-
treated, and two websites expressed a similar proportion using a different numerator and
denominator (17 in 1,000, 129 in 10,000). Two stated a different proportion, seemingly based
on a different reference group (women screened over 10 years: 10 in 2,000 or 1 in 200). Six
websites stated the ratio of deaths from breast cancer prevented to overdiagnosed cases. In
most cases this ratio was explicit, but a small amount of arithmetic was required from the
reader for one website. Five websites used estimates derived from the IUKPBCS report when
they stated the ratio to be 1:3 or (in one case) 5:17. However, one website stated the ratio to be
between 2:1 and 2.5:1 based on research from another group [34]. Furthermore, only three
websites referred to the IUKPBCS report explicitly when describing the magnitude of overdiag-
nosis. The proportion of screen-detected breast cancers that were overdiagnosed or overtreated
was stated to be 1 in 4 on one website but 1 in 5 on another. Notably, in seven instances relating
to the proportion of women screened who were overdiagnosed, or the ratio of breast cancer
deaths prevented to overdiagnosed cases, the statistics provided differed from those provided
in the information leaflet for the English NHS Breast Screening Programme. Finally, two web-
sites provided no statistics relating to overdiagnosis.
Australian websites: Despite providing similar conceptual information on overdiagnosis
and DCIS, there was relatively little overlap in the kinds of statistical information provided on
Australian and UK websites. Two Australian websites referred to World Health Organisation
estimates that one or two overdiagnoses of breast cancers occur for each breast cancer death
avoided and went on to state that the lifetime risk of overdiagnosis was 3% (although the
denominator was not explicitly stated). One other website stated four unique pieces of statisti-
cal information, namely i) that previous estimates of the proportion of overdiagnosed breast
cancers (out of all breast cancers) in the range of 5–13% had been superseded by more recent
studies, ii) that one recent review reported a range of 0–35% (median: 5–9%), iii) that another
review reported a range of 1–10%, and iv) the IUKPBCS reported estimates of overdiagnosis in
the range of 11–19%. Finally, this website referred to the approximate number of overdiagnoses
per 1,000 women screened biennially from age 50 to 74 (around 8; between 2 and 21). This sta-
tistic was also presented on one other website. No other statistical information was identified
on the remaining four websites.
Discussion
In this 2015–2016 assessment of the most prominent health websites providing information to
the general public on breast cancer screening, we found that almost all UK resources contained
information on overdiagnosis and described it using similar terms. In addition, most UK web-
sites explained that overdiagnosis would entail (unnecessary) treatment. Similarly, most UK
websites provided information on DCIS, its relevance to breast cancer screening, and either
related it to overdiagnosis explicitly or explained that it was unknown whether it would become
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invasive for a given person. The majority of UK websites also used some form of statistics in
order to illustrate the magnitude of overdiagnosis, and it was clear that the IUKPBCS review
had been influential. Although it was not always cited explicitly, the statistics most commonly
provided (the proportion of women screened who would be overdiagnosed and the ratio of
breast cancer deaths prevented to overdiagnosed breast cancers) were derived from the
IUKPBCS and there were few exceptions. However, although statistics on overdiagnosis were
consistent in many cases, the way that they were presented differed substantially. For example,
the probability of overdiagnosis for women undergoing screening was described as a propor-
tion out of 200, 1,000, or 10,000.
A majority of Australian websites also provided information related to overdiagnosis. How-
ever, explicit information that a breast cancer diagnosis could lead to unnecessary treatment
was less common. Most Australian websites also included information about DCIS although
this was more variable: two websites included most of our key information points whereas
remaining websites included either minimal information or no information. The Australian
website that contained the most information relating to DCIS was also the most detailed web-
site in terms of providing statistical information, including four estimates of the proportion of
breast cancers that were overdiagnoses; only three other websites provided statistical details.
This study was strengthened by the selection of websites from the first five pages of Google
search results. This was anticipated to generate a wide-ranging list of the most commonly
accessed websites, less frequently visited websites, and websites that most users would never
see. However, since search engine algorithms adjust results based on variables beyond the spe-
cific search terms (e.g. users’ locations), website listings are unlikely to have been exhaustive.
Our findings provide an updated assessment compared to a previous study that reviewed
websites in 2002, in which only 26% of websites were found to contain any information on
overdiagnosis and overtreatment, and only 37% referred to DCIS [9]. Notwithstanding possible
differences in website exclusion criteria between studies, this represents an appreciable change
over the past 14 years, most likely reflecting a greater emphasis placed on the issue (and per-
haps informed decision-making in general) among those who are professionally involved with
screening.
Although online information on overdiagnosis has become more widely available, the rela-
tively limited information about DCIS and statistics on Australian websites may be a concern;
to the extent that one considers it important to include this information, it may indicate scope
for improvement. However, this finding should be interpreted in the context of the fact that
several of the Australian organisations whose websites we included are related to one another,
meaning that some websites provided links to more detailed information contained elsewhere.
We also observed variation in how relevant statistical information was presented, especially
between UK websites. Given that public understanding of health statistics is limited [35], this
may be confusing to readers of multiple websites. In the context of the currently limited under-
standing of the concept of overdiagnosis among the general public (Ghanouni et al., under
review) [3–5], these findings suggest that more could be done to provide clearer and possibly
more consistent quantitative information on websites that describe breast cancer screening.
This is particularly important where statistics differ from those provided by healthcare provid-
ers themselves (e.g. the English NHS Breast Screening Programme and BreastScreen NSW), as
these are the set most likely to be encountered by women invited to screening. However, as the
most detailed Australian website notes, various estimates of the magnitude of overdiagnosis
exist and it is a matter of intense debate as to which are most accurate. Hence, an aim of pro-
viding consistent information would need to be balanced against another defensible goal of
informing women that there is uncertainty and that several sets of statistics exist.
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These findings suggest several possibilities for further research. The analysis consisted pri-
marily of websites that contained content produced by either a health charity or healthcare pro-
vider. However, an appreciable amount of public exposure to information on breast cancer
screening online is likely to occur on websites without a specific health focus (e.g. social media,
news, or video hosting and streaming services) [36]. It may be useful for future research to
explore the nature of overdiagnosis information on websites such as Twitter, YouTube, and
those of mainstream media outlets. Furthermore, in order to limit the role of subjective per-
sonal opinions in our evaluations, we limited our information coding to broad descriptive cate-
gories. Future studies could also examine other aspects relating to how that content is
communicated, such as information placement (e.g. if information on overdiagnosis was less
discoverable due to being located at the bottom of a lengthy page), tone (e.g. whether informa-
tion was empathetic or emotionally detached), and the use of visual elements to describe statis-
tics (e.g. graphs or icon arrays).
In conclusion, we found that a higher proportion of UK and Australian health websites
explained overdiagnosis and DCIS than websites accessed in 2002, although there was scope
for improvement within both sets. Descriptive information on the concepts was relatively con-
sistent, although information relating to DCIS and the relevant statistics were less prevalent
among Australian websites. Statistical information varied considerably across UK websites,
potentially causing confusion. Future work could extend the area of study to websites that are
not health-specific and describe more subtle characteristics of website information.
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